(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells

• Published in: Oncology letters Vol. 4; no. 3; pp. 546 - 550
• Main Authors: OGAWA, KENGO, HARA, TAKESHI, SHIMIZU, MASAHITO, NAGANO, JUNJI, OHNO, TOMOHIKO, HOSHI, MASATO, ITO, HIROYASU, TSURUMI, HISASHI, SAITO, KUNIAKI, SEISHIMA, MITSURU, MORIWAKI, HISATAKA
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.09.2012; Spandidos Publications UK Ltd
• Subjects: (-)-epigallocatechin gallate; 3-dioxygenase; Apoptosis; Cell growth; Colorectal cancer; colorectal cancer cells; Dendritic cells; Gene expression; indoleamine 2; interferon-γ; Kinases; Medical prognosis; Oncology; Phosphorylation; Proteins; signal transducer and activator of transcription 1; Studies; Tumors; United States > US; (-)-epigallocatechin gallate; indoleamine 2; interferon-γ; signal transducer and activator of transcription 1; 3-dioxygenase; colorectal cancer cells
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2012.761

Immune escape, the ability of tumor cells to avoid tumor-specific immune responses, occurs during the development and progression of several types of human malignancies, including colorectal cancer (CRC). Indoleamine 2,3-dioxygenase (IDO), the tryptophan catabolic enzyme, plays a significant role in regulating the immune response and provides tumor cells with a potent tool to evade the immune system. In the present study, we examined the effects of (-)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the inhibition of IDO expression induced by interferon (IFN)-γ in human CRC cells. We found that IFN-γ increased the expression levels of IDO protein and mRNA in HT29 and SW837 CRC cell lines. Treatment of SW837 cells with EGCG significantly decreased IFN-γ-induced expression of IDO protein and mRNA in a dose-dependent manner. Enzymatic activity of IDO, determined by the concentration of L-kynurenine in the culture medium, was also significantly inhibited by EGCG treatment. Phosphorylation of signal transducer and activator of transcription 1 (STAT1) induced by IFN-γ was also significantly inhibited by EGCG. Reporter assays indicated that EGCG inhibited the transcriptional activities of IDO promoters, IFN-stimulated response element and IFN-γ activation sequence, activated by STAT1 phosphorylation. These findings suggest that EGCG may exert antitumor effects on CRC, at least in part, by inhibiting the expression and function of IDO through the suppression of STAT1 activation. EGCG may, thus, serve as a potential agent for antitumor immunotherapy and be useful in the chemoprevention and/or treatment of CRC.